Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWU0I2)

Drug Name
Pralsetinib Drug Info
Synonyms
GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
129073603
CAS Number
CAS 2097132-94-8
TTD Drug ID
DMWU0I2
ACDINA Drug ID
D01355

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Proto-oncogene c-Ret (RET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [3]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [4]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [4]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [5]
Selpercatinib DMZR15V Non-small-cell lung cancer 2C25.Y Approved [6]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [7]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
GSK3179106 DM2KCIP Inflammatory bowel disease DD72 Phase 1 [9]
BOS172738 DM9L0D8 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
8 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 National Cancer Institute Drug Dictionary (drug name Zeteletinib).